http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20120119562-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2b4be2300a741a69aa1b8bb47a88899f |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2200-322 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-17 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 |
| filingDate | 2011-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_660b7b52bd50ed29c5c125b29e93bf32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd9fbec00d08e616988a4b4ac699a3fb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ad32ec58389fe0082a0834ee84a762d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_015f184ac56318d8bdf787861e1c3d52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_00f416942a8c44e07fbafb5e2c18a21a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e843cf5b682aa811ebfa4f8942298a7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e49163293848be3c9e5cbbff2448059b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea5679a75f399ac43ab86a1d51a52b69 |
| publicationDate | 2012-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20120119562-A |
| titleOfInvention | Composition for the prevention and treatment of brain diseases, including fusion protein and imipramine of therapeutic protein covalently bound with protein transport domain |
| abstract | Protein transport domains have been reported to be able to transport foreign polymers, including proteins, into living cells. The present inventors tested whether fusion proteins coupled with the protein transport domain can be more efficiently transported into neural cells such as astrocytes by adding imipramine, an antidepressant, and as a result, the catalyzed fusion protein was found to be time-dependent when imipramine was added. -And concentration-dependently introduced into astrocytes, reducing the cytotoxicity induced by hydrogen peroxide. In addition, the cell penetration rate was increased in the group of catalase fusion protein and imipramine, and as a result, the cell survival rate was higher compared to the group in which catalase fusion protein was added alone. In the low-bil ischemia model, catalase fusion protein showed a significant neuroprotective effect at the CA1 site of hippocampus. When catalase fusion protein and imipramine were treated together, the neuronal cell death at the CA1 site was higher than that of catalase fusion protein alone. Fat peroxidation was significantly reduced. Thus, these results indicate that imipramine increases the cellular introduction of fusion proteins. |
| priorityDate | 2011-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1033.